Clinical trial
ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases
NCT00294437 · Central European Cooperative Oncology Group, Other · Terminated
Key facts
| NCT number | NCT00294437 |
|---|---|
| Title | ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases |
| Official title | Randomised Open-label Multicenter Prosp. Clinical Study to Show the Efficacy of IV ZOMETA® 4mg for Prevention of Bone Metastases in Hormone-naïve High Risk Patients With Locally Advanced Prostate Cancer |
| Lead sponsor | Central European Cooperative Oncology Group, Other |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Zometa |
| Enrollment | 376 |
| Start date | Dec 1, 2003 |
| Primary completion | Dec 1, 2003 |
| Completion | Nov 1, 2007 |
| First posted | Feb 22, 2006 |
| Last update posted | May 1, 2012 |
| Countries | Austria, Bosnia and Herzegovina, Bulgaria, Croatia, Czechia, Estonia, Hungary, Lithuania, Montenegro, Poland, Romania, Russia and 4 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: